With a diversified portfolio of private cannabis and plant-based companies, we offer an exposure to a crisis-resilient market with clear structural growth.
We invest in companies that aim to improve the quality of life for millions of patients, while generating attractive financial returns for our investors.
Over the past three years, we have built an unprecedented network and deep understanding of the nascent industry in Europe, including its complex regulatory nuances. We know which segments and companies are primed for long term growth.
We provide investors with exposure to a diversified portfolio of European cannabis and plant-based companies, which today remain largely private due to the early growth stage of the industry. With strong legislative tailwinds spilling over from North America, the European plant-based health and wellness market is just getting started.
If the evolution of legal cannabis sales were compared to a football match, Canada would be playing its second half, the US its first half, and Europe would about to walk onto the pitch.
● Education – University of Colorado at Boulder; BSc in Journalism & Broadcasting
● Experience – +20 years of Investment Management and Banking; Partner at Brummer & Partners, VP at Deutsche Bank
● Other commitments – Board member at Amidea Sweden AB; Chairman of NORDx Pharma AB.
● Education – University of Fribourg; LL.B. & Geneva Bar; Fully Qualified Attorney
● Experience – +20 years of Private Equity experience in Legal Advisory and Investment Management
● Other commitments – Co-founder and Investment Advisor at Nasdaq-listed investment company NAXS AB (publ); Board member at Nasdaq First North-listed Flat Capital AB (publ)
● Education – Uppsala University; LL.M. & BSc in Economics
● Experience – +28 years of consulting CFO-roles at companies within finance, private equity, pharmaceutical etc. with international and public market experience
● Other commitments – currently CFO of the Nasdaq-listed investment company NAXS AB (publ)
● Education – European University; BBA & Insead; Executive Program
● Experience – +15 years of Board Experience; CEO, Director, and Operative Experience in the Cannabis Industry; previously CEO of leading US cannabis producer
● Other commitments –Director of Business Development at SHL Healthcare AB, Board member at Ramundberget Alpina AB, Offerator AB and US-based Nasdaq-listed SPAC in the cannabis industry,
● Education – University of Zurich; MD in Medicine, Dr. in Nuclear Medicine & IESE Business School; MBA
● Experience – +10 years of Medical Cannabis Research; Consulting for various leading European Cannabis Companies
● Other commitments – Senior Consultant and Manager at Executive Insight; Co-founder and Board member at Reyos
● Education – Karolinska Institutet; PhD in Medicine, Quantic School of Business and Technology; Executive MBA & MSc in Biomedicine; Lunds Universitet
● Experience – +15 years of Life Science and Consulting; currently CEO of Aprovix AB
● Other commitments – Co-owner and Managing Partner at inRikta Analys AB (Health Care Consulting) and co-founder of IM Care AB (data-driven service provider to the Swedish health care sector
● Education – University of Fribourg; LL.B. & Geneva Bar; Fully Qualified Attorney
● Experience – +20 years of Private Equity experience in Legal Advisory and Investment Management
● Other commitments – Co-founder and Investment Advisor at Nasdaq-listed investment company NAXS AB (publ); Board member at Nasdaq First North-listed Flat Capital AB (publ)